IFM Due has presented new stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of cancer.

BeiGene has divulged new GTPase KRAS (G12A mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate high-resolution disease models.

Using a knock-in mouse model of Brugada syndrome (BrS) with an SCN5A mutation identified in multiple BrS families (Scn5aG1746R/+), a team of scientists from various research institutions evaluated the effects of upregulation of MOG1 (ran guanine nucleotide release factor, RanGNRF) via adeno-associated virus serotype 9 (AAV9) vector delivery on BrS features.

The FDA has approved Eccogene's IND application to commence a phase I trial of the company's thyroid hormone receptor (THR) agonist ECC-4703 in the U.S.

Ipsen and Marengo Therapeutics have entered into a strategic partnership to advance two of Marengo's preclinical STAR (Selective T Cell Activation Repertoire) platform-generated candidates into the clinic.

Ozette Technologies has announced USD 26 million in Series A funding. The company is focused on artificial intelligence (AI)-powered single-cell immune discovery technology.

The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have discovered isoindolinone aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatement of cancer and fibrosis.

Cambridge Enterprise and European Molecular Biology Laboratory have presented new peptides derived from full-length factor V (FV) protein acting as T-cell activation inhibitors reported to be useful for the treatment of inflammatory bowel disease, type 1 diabetes, systemic lupus erythematosus, psoriasis, vasculitis, idiopathic pulmonary fibrosis, vitiligo and lupus nephritis, among other disorders.

3B Pharmaceuticals has divulged conjugates comprising fibroblast activation protein alpha (FAPalpha) inhibitors covalently linked to radiolabeled chelating agents through a linker acting as single-photon emission computed tomography (SPECT)/CT imaging agents reported to be useful for the diagnosis and treatment of cancer.